Raymond Joseph De Vera

Raymond Joseph De Vera

Auto-generated profile, based on publicly available information

Raymond Joseph De Vera

Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Ctr, Dept Surg,Coll Med, 123 Ta Pei Rd, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
CYChee-Chien Yong
Chee-Chien Yong
HYHsu-Ting Yen
Hsu-Ting Yen
YCYu-Fan Cheng
Yu-Fan Cheng
LDLeona Bettina Dungca
Leona Bettina Dungca
RVRaymond Joseph De Vera
Raymond Joseph De Vera
CCChao-Long Chen
Chao-Long Chen
The Meso-Rex bypass (MRB) is recognized as an effective treatment for portal hypertension secondary to extrahepatic portal vein occlusion (EHPVO) both in the pediatric and adult population, within or outside the context of liver transplantation. It is the preferred surgical treatment in most centers because not only does it addresses the portal hypertension, but also restores physiologic portal hepatopetal flow. However, the Rex recess, the landmark for this technique, may not be safely accessible in some patients. We present a 22-year-old male who underwent living donor liver transplant (LDLT) for neonatal hepatitis. He presented with variceal bleeding due to EHPVO at 13 years after transplant. Various endoscopic, radiologic, and surgical interventions were employed to address the recurrent gastrointestinal bleeding, but results have been unsatisfactory. We performed a meso-intrahepatic portal vein bypass (MIPVB), an innovative alternative to the MRB, for this patient with extensive post-operative adhesions, perihilar collaterals, and cavernous transformation. MIPVB creation in patients where the Rex recess is inaccessible is technically challenging. But with a multidisciplinary team approach, meticulous preoperative planning, and close follow-up, the authors have demonstrated that it is a safe and feasible option for patients with late-onset EHPVO after liver transplantation.